Innate Pharma (IPHA) - Net Assets
Based on the latest financial reports, Innate Pharma (IPHA) has net assets worth $-21.69 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($62.69 Million) and total liabilities ($84.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IPHA tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-21.69 Million |
| % of Total Assets | -34.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | -120.19% |
| 10-Year Change | -125.18% |
| Growth Volatility | 96.63 |
Innate Pharma - Net Assets Trend (2005–2025)
This chart illustrates how Innate Pharma's net assets have evolved over time, based on quarterly financial data. See IPHA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Innate Pharma (2005–2025)
The table below shows the annual net assets of Innate Pharma from 2005 to 2025. For live valuation and market cap data, see market cap of Innate Pharma.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-21.69 Million | -345.58% |
| 2024-12-31 | $8.83 Million | -79.41% |
| 2023-12-31 | $42.90 Million | -20.79% |
| 2022-12-31 | $54.15 Million | -49.60% |
| 2021-12-31 | $107.44 Million | -31.12% |
| 2020-12-31 | $155.97 Million | -28.26% |
| 2019-12-31 | $217.42 Million | +30.00% |
| 2018-12-31 | $167.24 Million | +94.56% |
| 2017-12-31 | $85.96 Million | -0.25% |
| 2016-12-31 | $86.17 Million | +19.57% |
| 2015-12-31 | $72.07 Million | -3.43% |
| 2014-12-31 | $74.63 Million | +85.24% |
| 2013-12-31 | $40.29 Million | +72.43% |
| 2012-12-31 | $23.36 Million | -12.25% |
| 2011-12-31 | $26.62 Million | -20.56% |
| 2010-12-31 | $33.52 Million | -28.87% |
| 2009-12-31 | $47.12 Million | +13.98% |
| 2008-12-31 | $41.34 Million | -16.66% |
| 2007-12-31 | $49.61 Million | -12.00% |
| 2006-12-31 | $56.37 Million | +180.93% |
| 2005-12-31 | $20.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Innate Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41558763000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.69 Million | % |
| Other Components | $408.98 Million | % |
| Total Equity | $-21.69 Million | 100.00% |
Innate Pharma Competitors by Market Cap
The table below lists competitors of Innate Pharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Libstar Holdings Ltd
JSE:LBR
|
$133.32 Million |
|
Coast Entertainment Holdings Ltd
AU:CEH
|
$133.34 Million |
|
Globe Union Industrial Corp
TW:9934
|
$133.38 Million |
|
AnaPass Inc
KQ:123860
|
$133.43 Million |
|
Aluko Co Ltd
KO:001780
|
$133.21 Million |
|
Dong Phu Rubber JSC
VN:DPR
|
$133.20 Million |
|
MOLECULAR PARTNERS ADS/1
F:6ML0
|
$133.19 Million |
|
Penta Teknoloji Urunleri Dagitim Ticaret AS
IS:PENTA
|
$133.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innate Pharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,834,000 to -21,694,761, a change of -30,528,761 (-345.6%).
- Net loss of 47,236,115 reduced equity.
- Other comprehensive income decreased equity by 27,000.
- Other factors increased equity by 16,734,354.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-47.24 Million | -217.73% |
| Other Comprehensive Income | $-27.00K | -0.12% |
| Other Changes | $16.73 Million | +77.14% |
| Total Change | $- | -345.58% |
Book Value vs Market Value Analysis
This analysis compares Innate Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $1.35 | $1.79 | x |
| 2006-12-31 | $3.17 | $1.79 | x |
| 2007-12-31 | $1.98 | $1.79 | x |
| 2008-12-31 | $1.61 | $1.79 | x |
| 2009-12-31 | $1.79 | $1.79 | x |
| 2010-12-31 | $0.90 | $1.79 | x |
| 2011-12-31 | $0.71 | $1.79 | x |
| 2012-12-31 | $0.62 | $1.79 | x |
| 2013-12-31 | $1.04 | $1.79 | x |
| 2014-12-31 | $1.49 | $1.79 | x |
| 2015-12-31 | $1.35 | $1.79 | x |
| 2016-12-31 | $1.60 | $1.79 | x |
| 2017-12-31 | $1.58 | $1.79 | x |
| 2018-12-31 | $2.85 | $1.79 | x |
| 2019-12-31 | $3.25 | $1.79 | x |
| 2020-12-31 | $1.98 | $1.79 | x |
| 2021-12-31 | $1.35 | $1.79 | x |
| 2022-12-31 | $0.68 | $1.79 | x |
| 2023-12-31 | $0.62 | $1.79 | x |
| 2024-12-31 | $0.11 | $1.79 | x |
| 2025-12-31 | $-0.24 | $1.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innate Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1694.87%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-50.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -30.55% | -471.46% | 0.05x | 1.23x | $-8.14 Million |
| 2006 | -10.72% | -97.53% | 0.09x | 1.23x | $-11.68 Million |
| 2007 | -17.98% | -62.41% | 0.23x | 1.27x | $-13.88 Million |
| 2008 | -23.83% | -76.23% | 0.21x | 1.47x | $-13.99 Million |
| 2009 | -31.04% | -189.55% | 0.12x | 1.36x | $-19.34 Million |
| 2010 | -40.75% | -316.16% | 0.09x | 1.43x | $-17.01 Million |
| 2011 | -26.22% | -59.45% | 0.20x | 2.26x | $-9.64 Million |
| 2012 | -13.69% | -30.83% | 0.21x | 2.07x | $-5.54 Million |
| 2013 | -7.18% | -23.19% | 0.22x | 1.39x | $-6.92 Million |
| 2014 | -26.33% | -2166.15% | 0.01x | 1.22x | $-27.11 Million |
| 2015 | -9.31% | -37.45% | 0.06x | 4.25x | $-13.91 Million |
| 2016 | 14.67% | 22.51% | 0.20x | 3.27x | $4.02 Million |
| 2017 | -56.29% | -148.28% | 0.13x | 2.97x | $-56.98 Million |
| 2018 | 1.82% | 3.82% | 0.18x | 2.70x | $-13.68 Million |
| 2019 | -9.55% | -30.10% | 0.17x | 1.85x | $-42.50 Million |
| 2020 | -41.02% | -91.70% | 0.23x | 1.97x | $-79.58 Million |
| 2021 | -49.15% | -436.01% | 0.05x | 2.49x | $-63.55 Million |
| 2022 | -107.30% | -100.74% | 0.28x | 3.84x | $-63.52 Million |
| 2023 | -14.59% | -14.59% | 0.30x | 3.38x | $-12.76 Million |
| 2024 | -560.01% | -391.97% | 0.11x | 12.57x | $-50.35 Million |
| 2025 | 0.00% | -1694.87% | 0.04x | 0.00x | $-45.07 Million |
Industry Comparison
This section compares Innate Pharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innate Pharma (IPHA) | $-21.69 Million | -30.55% | N/A | $133.24 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more